Title of Invention

APPARATUS FOR REDUCING THE EFFECTS OF GENERAL ANESTHETICS

Abstract An apparatus for reversing inhaled anesthesia, which is configured to be positioned along a breathing circuit or anesthesia de delivery circuit, includes a filter for removing one or more anesthesia agents from gasses passing threat rough as well as a component for elevating CO2 level in gasses that are to be inhaled by an individual, The apparatus is configured to be positioned between Y connector of the breathing circuit and portion of the breathing circuit that interface with the individual, The CO2 level elevating components facilitates an increase in the ventilation of the individual without resulting in a significant decrease in the individual’s P2CO2 level and thus, a decrease in the rate at which blood flows through the individual’s brain. The apparatus may cause an increase in a rate of the anesthetized individual’s ventilation while causing individual’ to inhale gasses with elevated amount of CO2 and while filtering anesthetic agent from such gasses.
Full Text WO 2004/098688 PCT/US2004/012291
-1-
APPARATUS FOR REDUCING THE
EFFECTS OF GENERAL ANESTHETICS
PRIORITY CLAIM
This application claims the benefit of the filing date of United States Provisional
Patent Application Serial Number 60/466,934, filed May 1,2003, for "Apparatus and
Techniques for Reducing the Effects of General Anesthetics," and United States Non-
Provisional Patent Application Serial Number 10/680,469, filed October 7,2003, for
"Apparatus and Techniques for Reducing the Effects of General Anesthetics," pending.
TECHNICAL FIELD
The present invention relates generally to apparatus and techniques for
reversing the effects of inhaled general anesthetics. More particularly, the present
invention relates to use of ventilation and rebreathing apparatus and, optionally,
respiratory monitoring apparatus, in conjunction with one another to reverse the effects
of inhaled general anesthetics.
BACKGROUND
General anesthesia is often administered to individuals as surgical procedures
are being performed. Typically, an individual who is subject to general anesthesia is
"hooked up" to a ventilator by way of a breathing circuit One or more sensors may
communicate with the breathing circuit to facilitate monitoring of the individual's
respiration, the anesthesia, and, possibly, the individual's blood gases and blood flow.
One or more anesthetic agents are typically administered to the individual through the
breathing circuit
Examples of breathing circuits that are used while anesthesia is being
administered to a patient indude circular breathing circuits, which are also referred to
in the art as "circle systems," and Mapleson or Bain type breathing circuits, which are
also referred to herein as Bain systems for the sake of simplicity.
Circle systems are typically used with adult patients. The expiratory and
inspiratory limbs of a breathing circuit of a circle system communicate with one
another, with a carbon dioxide remover, such as a soda lime can, being disposed
therebetween. As the expiratory and inspiratory limbs communicate with one another,

WO 2004/098688 PCT/US2004/012291
-2-
a circle system will typically include two or more sets of one-way valves to prevent a
patient from rebreafhing just-expired, CO2-rich gases.
Bain systems are typically used with smaller patients (e,g., children). Bain
systems include linear tubes through which both inspiratory and expiratory gases flow.
Fresh gases are typically directed toward a patient interface to remove the just-expired
gases therefrom before the patient can rebreathe them. As long as the fresh gas flow is
higher than the flow of the patient's ventilation, there is little or no rebreathing.
When a general anesthesia is administered to an individual, respiratory or
inhaled anesthetics are delivered to a patient in low concentrations, typically being
diluted to a concentration of about 1% to about 5%, depending on the type of anesthetic
agent used. As the individual inhales a general anesthetic agent, the anesthetic agent is
carried into the lungs, where it enters the bloodstream, and is carried by the blood to
various other body tissues. Once the concentration of the anesthetic reaches a sufficient
level, or threshold level, in the brain, which depends upon a variety of
individual-specific factors, including the size and weight of the individual, the '
individual becomes anesthetized. The individual remains anesthetized so long as the
concentration of the anesthetic agent in the brain of the individual remains above the
threshold level.
Once the procedure, typically surgery, for which the general anesthesia is given,
has been completed, it is usually desirable to reverse the effects of the general
anesthetic as soon as possible. Reversal of the effects of general anesthesia allows the
surgical team to vacate the operating room, thereby freeing it up for subsequent
surgeries and possibly reducing the cost of surgery, and also permits the anesthetist to
tend to other patients, and conserves the typically expensive anesthetic agents that are
used. In addition, for safety reasons, it is desirable to minimize the time an individual
is under general anesthesia. Other benefits of quickly reversing anesthesia include
better cognitive function for elderly patients immediately following surgery and
enabling patients to protect their own airway sooner
Reversal or discontinuation of the general anesthetic state requires that levels of.
the anesthetic agent in the brain decrease below the threshold level, or that the
anesthetic agent be removed from the individual's brain.
It has long been known that activated charcoal and other substances can be used
to selectively adsorb gaseous anesthetic agents. Accordingly, activated charcoal has

WO 2004/098688 PCT/US2004/012291
-3-
found conventional use in adsorbers, such as that described in U.S. Patent 5,471,979,
issued to Psaros et al., that prevents anesthetic agents from escaping the breathing
circuit and entering the operating room. In this regard, activated charcoal adsorbers are
typically placed in the exhaust flow of the anesthesia delivery system. The potentially
deleterious effects of exhaust anesthetic gases into the operating room are thereby
avoided. Further, as most halocarbon anesthetics are considered to be atmospheric
pollutants, the charcoals or other adsorbents of conventional anesthetic agent adsorbers
prevent pollution that may be caused if gaseous anesthetic agents were otherwise
released into the environment.
U.S. Patent 5,094,235, issued to Westenskow et al. (hereinafter "Westenskow"),
describes the use of activated charcoal to hasten the removal of gaseous anesthetic
agents from breathing circuits. While such a technique would be useful for preventing
the reinhalation of previously exhaled anesthetic agents, more could be done to hasten
the rate at which anesthetic agents are removed from the individual's brain.
Typically, the rate at which blood flows through the brain and an individuaTs
breathing rate and breathing volume are the primary factors that determine the rate at
which the levels of anesthetic agent are removed from the brain of the individual. The
rate of blood flow through the brain is a determining factor because the blood carries
anesthetic agents away from the brain and to the lungs. The breathing rate and
breathing volume are important since they increase the rate at which anesthetic agent
may be removed from the Wood and transported out of the body through the lungs.
Hyperventilation has been used to increase the breath volume and/or rate of an
individual and, thereby, to facilitate the removal of anesthetic agents from the
individual's lungs. However, hyperventilation typically results in a reduced level of
carbon dioxide (CO2) in blood of the individual (PaCO2). When PaCO2 levels are
decreased, the brain is less likely to signal the lungs to breathe on their own and the
patient remains dependent on the ventilation from an artificial respirator. See U.S.
Patent 5,320,093, issued to Reamer (hereinafter "Raemer"). Additionally, the reduced
PaCO2 levels that result from hyperventilation are known to cause a corresponding
reduction in the rate at which blood flows through the brain, which actually decreases
the rate at which the blood can carry anesthetic agents away from the brain.
Rebreathing processes, in which an individual "rebreathes" previously exhaled,
. CCVrich air, have been used to prevent significant decreases in PaCC>2 levels during

WO 2004/098688 PCT/US2004/012291
-4-
such hyperventilation. The apparatus that have been conventionally used to effect such
processes, however, do not filter anesthetic agent from the exhaled air before the
individual rebreathes the same. Consequently, the patient also rebreathes the
previously exhaled anesthetic agent, which effectively prolongs the process of
reversing the general anesthesia.
The computerized system described in Raemer was designed to overcome
purported deficiencies with hyperventilation and rebreathing. The system of Raemer
infuses CO2 from an external source into the breathing circuit and, thus, into the
individual's lungs (le., the CO2 is not rebreathed by the individual) as general
anesthesia is being reversed to speed the rate of reversal and, thus, recovery of the
individual from the general anesthesia. The teachings of Raemer with respect to
infusion of CO2 from an external source are limited to avoidance of reintrodudng
anesthetic agents into the individual's brain while increasing the individuaTs PaCO2 to
a level that will facilitate reinitiation of spontaneous breathing by his or her brain as
early as possible. As the technique and system that are taught in Raemer do not include
increases in the breathing rate or breathing volume of an individual, they do not
accelerate the rate at which an individual recovers from anesthesia.
Accordingly, there are needs for processes and apparatus which increase the rate
at which blood carries anesthetic agents from the brain, as well as the rate at which the
lungs expel the anesthetic agents from the body in order to minimize the time required
to reverse the levels of anesthetic agents in the brain to reverse the effects thereof.
DISCLOSURE OF INVENTION
The present invention includes methods and apparatus for accelerating the rate
at which an individual recovers from general anesthesia, or for reversing the effects of
anesthetic agents. These methods and apparatus maintain or increase the rate at which
blood flows through the individual's brain, increase the individual's rate of respiration
and respiratory volume, and prevent the individual from reinhaling previously exhaled
anesthetic agents.
A method according to the present invention includes increasing the rate at
which the individual inhales or the volume of gases inhaled by the individual, which
may be effected with a ventilator, or respirator, while causing the individual to at least
periodically breathe gases including an elevated fraction of CO2. This may be effected

WO 2004/098688 PCT/US2004/012291
-5-
by causing the individual to rebreathe at least some of the gases that the individual has
already exhaled or by otherwise increasing the amount of CO2 in gases that are to be
inhaled by the individual. The rebreathed gases are filtered to at least partially remove
some of the previously exhaled anesthetic agent or agents therefrom. It is currently
preferred that substantially all anesthetic agents be removed from the exhaled gases
prior to rebreathing thereof.
An apparatus that incorporates teachings of the present invention is configured
to facilitate breathing by an individual at a rapid (i.e., above-normal) rate, while
maintaining CO2 levels in the blood individual's blood, thereby at least maintaining the
rate at which blood flows to and through the individual's brain. Such an apparatus
includes a filter to selectively remove anesthetic agents from gases that have been
exhaled by the individual, as well a component that is configured to effect partial
rebreathing by the individual, which is also referred to herein as a **rebreathing
element," or another component which is configured to increase the levels of CO2
inhaled by the individual. The rebreathing or other CO2 level-elevating component of
the apparatus facilitates an increase in the rate of ventilation of the individual, while
CO2 levels in blood of the individual (i.e., PaCO2) remain normal or elevated. The
rebreathing or other CO2 level-elevating component further allows the patient to be
mechanically ventilated using a respirator at a high volume or rate while maintaining
high or normal levels of CO2.
Other features and advantages of the present invention will become apparent to
those of ordinary skill in the art mrough consideration of the ensuing description, the
accompanying drawings, and the appended claims.
BRIEF DESCRIPTION OF DRAWINGS
In the drawings, which illustrate various aspects of exemplary embodiments of
the present invention:
FIG. 1 is a schematic representation of an example of an anesthesia reversal
system according to the present invention, including at least a portion of a breathing
circuit, an element for increasing a concentration of carbon dioxide inhaled by a subject
that is recovering from anesthesia, and an anesthesia filter and Y-connector positioned
along the breathing circuit;

WO 2004/098688 PCT/US2004/012291
-6-
FIG. 2 schematically depicts an exemplary embodiment of the anesthesia
reversal system shown in FIG. 1, which includes a rebreathing tube positioned along a
breathing circuit, between the anesthesia filter and the Y-piece, which are also
positioned along the breathing circuit;
FIG. 3 is a cross-sectional representation of another exemplary embodiment of
the anesthesia reversal system of FIG. 1, in which a rebreathing tube which extends
from and back to the anesthesia filter;
FIG. 4 is a cross-sectional representation of another embodiment of anesthesia
reversal system of the present invention, in which the anesthesia filter thereof includes
an additional dead space volume which is configured to effect rebreathing;
FIG. 5 is a cross-sectional representation of still another embodiment of
anesthesia reversal system that incorporates teachings of the present invention, in which
the anesthesia filter includes a volume-adjustable dead space to effect rebreathing;
FIGs. 6A and 6B are schematic depictions of yet another embodiment of
anesthesia reversal system of the present invention, in which one or more conduits and
valves are positioned between inspiratory and expiratory limbs that branch off of the
Y-connectors;
FIG. 7 schematically depicts use of an anesthesia reversal system according to
the present invention along a conventional circular system;
FIG. 8 schematically illustrates use of an anesthesia reversal system of the
present invention with a conventional Bain system; and
FIG. 9 is a schematic representation of yet another embodiment of anesthesia
reversal system of the type shown in FIG. 1, in which the element that increases a
concentration of carbon dioxide inhaled by the subject comprises a carbon dioxide
infuser.
BIEST MODE(S) FOR CARRYING OUT THE INVENTION
With reference to the FIG, 1, an anesthesia reversal system 10 according to the
present invention, which maybe positioned along a portion of a breathing circuit 50,
between an individual I and a Y connector 60, and includes a filter 20 and a rebreathing
component 30. An inspiratay limb 52 and an expiratory limb 54 may be coupled to Y
connector 60 and, thus, to breathing circuit 50. Notably, the inspiratory and expiratory
limbs of some breathing circuits are coaxial. Nonetheless, the junction between the

WO 2004/098688 PCT/US2004/012291
-7 -
inspiratory and expiratory hoses of such breathing circuits is still referred to as a "Y
connector."
As depicted, filter 20 is positioned near the endotracheal tube for an intubated
patient or over the mouth and/or nose of an individual I when breathing through a mask
or mouthpiece so as to remove exhaled anesthetic agents before they flow into the
remainder of anesthesia reversal system 10, where they might otherwise be adsorbed by
the surfaces of anesthesia reversal system to remove inhalation anesthetics anil be
subsequently inhaled by the individual. Of course, placement of filter 20 at alternative
locations of anesthesia reversal system 10 is also within the scope of the present
invention, so long as filter 20 is positioned between the individual I and rebreathing
component 30.
Filter 20 may include a housing 22 with a proximal (relative to individual I)
port 24 and a distal port 26, which, in the depicted example, are on opposite sides of
filter 20. In addition, an anesthesia filter member 28 is contained within housing 22, in
communication with both proximal port 24 and distal port 26.
Proximal port 24 and distal port 26 may both be configured for connection to
standard breathing circuit fittings. For example, proximal port 24 and distal port 26
may be configured to connect to standard 15 mm or 22 mm respiratory fittings. As
such, once reversal of general anesthesia or other inhaled anesthesia is desired, filter 20
may be positioned along a breathing circuit 50 which is already in communication with
an airway {Le., the mouth ornose, trachea, and lungs) of individual I.
Anesthesia filter member 28 may comprise any type of filter which is known to
selectively adsorb one or more types of anesthetic agents. By way of example and not
to limit the scope of the present invention, anesthesia filter member 28 may comprise
an activated charcoal, or activated carbon, filter, a crystalline silica molecular sieve, a
lipid-based absorber (e.g., which operates in accordance with the teachings of U.S.
Patent 4,878,388 to Loughlin et al., the disclosure of which is hereby incorporated
herein in its entirety by this reference), a condensation-type filter, or any other type of
filtering mechanism which captures or otherwise removes anesthetic vapors from the
gases that have been exhaled by individual I. If filter member 28 comprises a
paniculate material, such as activated charcoal or crystalline silica, the participate
material may be contained by a porous member, a screen, or the like.

WO 2004/098688 PCT/US2004/012291
-8-
As anesthesia filter member 28 communicates with both proximal port 24 and
distal port 26, it will remove anesthetic agents from gases that are inhaled by
individual I, as well as from gases that are exhaled by individual I.
Optionally, filter 20 may also include an antimicrobial filter member 29 of a
type known in the art, such as 3M FILTRETE filter media or other electrostatic
polypropylene fiber based filter media. Like anesthesia filter member 28, antimicrobial
filter member 29 communicates with breathing circuit 50 {e.g., by way of proximal
port 24 and distal port 26 of filter 20). Accordingly, antimicrobial filter member 29 is
positioned to receive substantially all of the gases that are inhaled and exhaled by
individual 1 and, thus, to remove bacteria, viruses, or other pathogens from those gases.
Of course, anesthesia reversal systems that include antimicrobial filters that are separate
- from filter 20 are also within the scope of the present invention.
As shown in FIG. 1, filter 20 and rebreatning element 30 are in direct
communication with one another. As will be shown in greater detail hereinafter,
rebreathing element 30 may actually be a part of filter 20, rather than separate
therefrom.
Rebreathing element 30 may be configured to provide a volume or an amount of
dead space which will maintain a particular level of CO2 in the blood (Le., PaCOa) of
individual I. In the depicted example, rebreathing element 30 comprises a section 32 of
expandable tubing that can be extended to increase or compressed to decrease the
amount of dead space for containing previously exhaled gases which are to be
rebreathed by individual I. Of course, other types of rebreathing apparatus, such as one
of those (excepting the tracheal gas insufflation device) described in U.S.
Patent 6,227,196, issued to On* et al., the disclosure of which is hereby incorporated
herein in its entirety by this reference, or any other known type of partial rebreathing
apparatus, may be.used in anesthesia reversal system 10 as rebreathing element 30.
It is also within the scope of the present invention to include another element,
such as a respiratory flow seasor or gas sampling port 40a therefor, or a capnometer or
gas sampling port 40b therefor, as known in the art, at any position along an anesthesia
reversal system 10 according to the present invention (., close to individual I,
between filter 20 and rebrerfiing element 30, close to Y connector 60, etc.). For
example, when gas sampling ports 40a, 40b are used, they may be of conventional
configuration (e.g., for fad&ating gas sampling at a rate of about 50 ml/min to about

WO 2004/098688 PCT/US2004/012291
-9-
250 rnl/min), such as fittings that are configured to be disposed at an end or along the
length of breathing circuit 50 or an inspiratory or expiratory limb 52,54 in
communication therewith.
Turning now to FIGs. 2 through 6, specific examples of anesthesia reversal
systems that incorporate teachings of the present invention are shown.
The embodiment of anesthesia reversal system 10' shown in FIG. 2 includes a
rebreathing component 30' that comprises a section of rebreathing conduit 31', which
communicates with breathing circuit 50 at two locations 34' and 35' between filter 20
and Y connector 60. Rebreathing conduit 31' may include a section 32' which is
volume-adjustable in a manner known in the art (e.g., by way of corrugations, etc.).
One or more valves 36', flow restrictors 37', or a combination thereof may be
positioned along breathing circuit 50 or rebreathing conduit 31' to control the flow of
gases into and out of conduit 31'.
Another embodiment of anesthesia reversal system 10", which is shown in
FIG. 3, includes a rebreathing component 30" that communicates directly with a
filter 20" rather than with breathing circuit 50. As shown, rebreathing component 30"
may be configured as a loop of conduit 31". One or both ends 38" and 39" of
conduit 31 may communicate with filter 20" at a location which is on the distal side of
anesthesia filter member 28 relative to the location of individual I (FIG. 1) (e.g.y
between anesthesia filter member 28 and distal port 26) such that are filtered gases
before and/or after passage thereof through conduit 31". Like rebreathing
component 30' (FIG. 2), rebreathing component 30" may include a volume-adjustable
section 32".
HG. 4 depicts another embodiment of anesthesia reversal system 10"', in which
filter 20'" is configured to provide a dead space volume 30'" in which at least some
carbon dioxide rich gases, are collected as individual I exhales. As shown, dead space
volume 30'" is located on the distal side of anesthesia filter member 28, such that the
exhaled gases that have collected therein are filtered as they flow therein and, later, as
they are drawn therefrom {e.g., as individual I (FIG. 1) subsequently inhales).
Yet another embodiment of anesthesia reversal system 10"" that incorporates
teachings of the present invention is pictured in FIG. 5. Anesthesia reversal
system 10"" is much like anesthesia reversal system 10'", which are shown in and
described with reference toHG. 4. The primary difference between anesthesia reversal

WO 2004/098688 PCT/US2004/012291
-10-
system 10'"' and anesthesia reversal system 10'" is that the dead space volume 30"" of
anesthesia reversal system 10"", which is at least partially defied by body 22"" of
filter 20"", is adjustable, for example, by enlarging or reducing the amount of space
occupied by body 22"" (e.g., by the illustrated sliding motion or as otherwise will be
readily apparent to those of ordinary skill in the art
As another alternative, pictured in FIGs. 6A and 6B, an anesthesia reversal
system 10'"" of the present invention may include one or more shunt lines 56'""
positioned between an inspiratory limb 52'"" and an expiratory limb 54""' to provide a
selectively sized dead space in the circuit. La this embodiment, inspiratory limb 52"'"
and expiratory limb 54'"" act as part of the dead space. A two-way shunt valve 58'"" is
positioned along each shunt line 56'"" to selectively direct the flow of inspired and
expired gas.
During normal or baseline breathing, as depicted in FIG. 6A, the two-way shunt
valve 58'"" will be in a closed position and exhaled gases, which are represented by the
shaded area, will enter the expiratory limb 54"".
In order to facilitate rebreathing, as pictured in FIG. 6B, two-way shunt
valve 58'"" is opened, permitting exhaled gases to fill a portion of inspiratory
limb 52'"", substantially all of expiratory limb 54"'", and shunt line 56'"", all of which
serve as dead space.
The dead space may be rendered adjustably expandable by using expandable
conduit for all or part of one or more of inspiratory limb 52'"", expiratory limb 54'"",
and shunt line 56'"".
Turning now to HGs. 7 and 8, use of an anesthesia reversal system 10 of the
present invention in combination with various anesthesia delivery systems is shown.
In FIG. 7, a circle system 70 is illustrated. Circle system 70, which includes an
interconnected (e.g., in tjie configuration of a circle, or loop) inspiratory limb 52' and
expiratory limb 54', Inspiratory limb 52' and expiratory limb 54' are coupled to a Y
connector 60 which, in turn, is coupled to a breathing circuit 50'. Breathing circuit 50'
is configured to interface with an individual I (FIG. 1) in a known manner (e.g., by
intubation, with a mask, with a nasal cannula, etc.). Circle system also includes at least
two one-way valves 72 and 74, which are positioned across inspiratory limb 52' and
expiratory limb 54', respectively, at opposite sides of Y connector 60. One way
valves 72 and 74 restrict the flow of gases through circle system 70 to a single

WO 2004/098688 PCT/US2004/012291
-11-
direction, such that expired gases are prevented from flowing directly into inspiratory
limb 52' and to prevent individual I from inhaling gases directly from expiratory
limb 54'.
Inspiratory limb 52' of circle system 70 includes at least one gas inlet 75, such
as a port that facilitates coupling to an anesthesia delivery system 300, a mechanical
ventilator, or a breathing bag, or which permits air from an environment external to
circle system 70 {e.g., an operating room, a patient room in a hospital, etc.) to flow
therein. An expiratory element 76, such as an expiratory spill valve of a known type is
positioned along expiratory limb 54' of circle system 70.
As shown, expiratory limb 54' and expiratory limb 52' are joined at a location
which is distal relative to Y connector 60 and individual I by a carbon dioxide removal
element 77, such as a soda lime canister. As one-way valve 72 prevents exhaled gases
entering inspiratory limb 52', the exhaled gases are directed through expiratory limb 54'
and, depending upon the positioning of a bypass valve 78 positioned along expiratory
limb 54', possibly into carbon dioxide removal element 77, which reduces the amount
of carbon dioxide present in such gases.
Additionally, circle system 70 includes an anesthesia reversal system 10. As
shown, anesthesia reversal system selectively communicates, by way of bypass
valve 78, with expiratory limb 54' of circle system 70 and is positioned in parallel to
carbon dioxide removal element 77. The volume of dead space that may be present
within circle system 70 depends upon whether or not expiratory element 76 causes
exhaled gases to remain within expiratory limb 54' and upon whether bypass valve 78
is positioned to permit exhaled gases to bypass carbon dioxide removal element 77. In
addition, when a mechanical ventilator is coupled to gas inlet 75, the volume of dead
space within circle system TO depends upon the proximity of the gas inlet 75 to a
junction 80 of anesthesia,reversal system 10 with inspiratory limb 52'.
If expiratory element 76 is at least partially closed, depending upon the
positioning of bypass valve 78, at least some of the gases that have been exhaled by
individual I and which are flowing through expiratory limb 54' may be diverted from
carbon dioxide removal element 77 into anesthesia reversal system 10. If bypass
valve 78 is adjustable to more than two positions, exhaled gases may be directed into
both anesthesia reversal system 10 and carbon dioxide removal element 77. Thus, it
may be possible to carefullyiegulate the amounts of exhaled gases that are directed into

WO 2004/098688 PCT/US2004/012291
-12-
anesthesia reversal system 10 and carbon dioxide removal element 77, providing
control over the amount of carbon dioxide that is rebreathed by individual L Further, if
bypass valve 78 is positioned such that the previously exhaled gases flow through
anesthesia reversal system 10, the amount of carbon dioxide that remains in gases that
pass through anesthesia reversal system 10 will be relatively high, while the amount of
anesthesia present in such gases will be reduced by filter 20.
Then, when individual I inhales or is caused to inhale, at least a portion of the
gases that are inhaled {i.e., the gases that remain within breathing circuit 50' and
anesthesia reversal system 10) will be previously exhaled, CO2-rich gases.
As circle system 70 may itself serve as a dead space from which an individual I
may be caused to rebreathe previously exhaled, carbon dioxide rich gases, an anesthesia
reversal system 10 that is used in a circle system 70 may lack additional dead space,
such as a rebreathing element 30.
Referring now to FIG. 8, a Bain system 90 that incorporates teachings of the
present invention is depicted. Bam system 90 includes a linear breathing circuit 50", a
patient interface 92 located at one end 51" of breathing circuit 50", and a fresh gas
inlet 94, which is configured to communicate with an anesthesia delivery system 300 of
a known type, a mechanical ventilator, a breathing bag, or the environment external to
Bain system 90, positioned along the length of breathing circuit 50". In addition, Bain
system 90 includes an anesthesia reversal system 10 that communicates with breathing
circuit 50". Anesthesia reversal system 10 is preferably positioned proximate to patient
interface 92 so as to optimize the amount of anesthesia removed from the exhaled gases
and, thus, rninimize the amount of anesthetic agent rebreathed by an individual I as the
affects of the anesthesia are being reversed.
While FIGs. 2 througfe 8 illustrate various systems that are useful for providing
a dead space volume from vrtjich an individual I may rebreathe as individual I is being
withdrawn from anesthesia, any other method, apparatus, or system that induces
rebreathing of carbon dioxide in a mechanical breathing circuit for the purpose of
reversing the affects of anesthesia on an individual is also within the scope of the
present invention.
Turning now to FIG. 9, an anesthesia reversal system 110 that includes a carbon
dioxide infusion element 130 rather than a rebreathing component is depicted. As
illustrated, carbon dioxide infusion element 130 communicates with a breathing

WO 2004/098688 PCT/US2004/012291
-13-
conduit 150. A filter 120 of anesthesia reversal system 110 is also positioned along
breathing conduit 150, proximate to individual I (FIG. 1), so as to reduce that the
amount of anesthesia in gases that are exhaled by individual I and, thus, to minimize
the amount of anesthesia that remains in any gases that are withdrawn from breathing
conduit 150 and rebreathed by individual L
With returned reference to FIG. 1 (although anesthesia reversal system 110
shown in and described with reference to FIG. 9 may be used in a similar manner),
anesthesia reversal system 10 may be used by placing the same in communication with
a breathing circuit or anesthesia delivery circuit (e.g., those shown in FIGs. 7 and 8). It
is currently preferred that filter 20 be positioned proximate to individual I and that
rebreathing element 30 be positioned closer to Y connector 60. In the case of
anesthesia recovery system 110 (FIG. 9), the position of carbon dioxide infusion
element 130 relative to that of filter 120 is irrelevant
A dead space (eg., in the form of the volume within a rebreathing element 30)
may be adjusted by an anesthetist to provide the desired volume of dead space therein
in order to facilitate rebreathing. For example, when the dead space volume is at least
partially located within corrugated tubing, the dead space volume may be adjusted by
extending or contracting the length of the corrugated tubing. As another example,
when a fixed volume of dead space is present, or even with a volume-adjustable dead
space, the amount of carbon dioxide within the dead space may be tailored by adjusting
the flow of "fresh" gases, including recycled gas from which carbon dioxide has been
removed. When the flow of "fresh" gases is lower than the flow of individual Ps
ventilation, rebreathing of gases within the dead space may occur.
Once anesthesia reversal system 10 has been positioned in communication with
i a breathing circuit or anesthesia delivery system, gases that are exhaled by individual I
pass into and through filter 20, which removes at least some anesthetic agents from the
exhaled gases. At least a portion of the volume of the filtered, exhaled gases enters and
at temporarily remains wifliin the dead space (,, rebreathing element 30). Also, by
reducing levels of anesthetic agents in gases that are exhaled by individual I, filter 20
may effectively reduce levels of anesthetic agents that escape into the environment
(e.g.f the operating room, recovery room, atmosphere, etc.) when individual I exhales.
When individual I inhales, at least a portion of the inhaled gases are drawn from
the dead space (e.g., from inbreathing element 30), with any other gases being drawn

WO 2004/098688 PCT/US2004/012291
-14-
from either the air or from a source of inspiratory gases that communicate with a
ventilator. As the inhaled gases are drawn through breathing circuit, they pass through
filter 20, where at least some of the remaining anesthetic agents therein are removed
therefrom. Notably, in most anesthesia systems, very high concentrations of oxygen (>
90%) are used. Thus, individual I may rebreathe the same gas many times and still be
sufficiently oxygenated.
It is currently preferred that partial rebreathing processes (i.e., only a portion of
the gases inhaled by the patient were previously exhaled, while the other portion of
gases are "fresh") be used in reversing the effects of inhaled anesthesia. This is
because individual I requires some oxygen during the reversal. Of course, the use of
total rebreathing processes is also within the scope of the invention. The manner in
which rebreathing is effected may be varied or controlled to provide the desired affects,
while providing individual I with sufficient oxygen.
Of course, a gas sensor and monitor 210 (e.g., an anesthetic gas monitor of a
known type) that measures carbon dioxide or oxygen may be used to monitor the
ventilatory gases of individual I. A respiratory flow sensor and monitor 212 may also
be used to monitor the flow of ventilation of individual I. Gas concentrations may be
determined by a processing element 220 (e.g., a computer processor or controller, a
smaller group of logic circuits, etc:) that communicates with gas sensor and
monitor 210 and flow sensor and monitor 212, as known in the art. If the carbon
dioxide or oxygen levels (e.g.f blood gas content, respiratory fraction, etc.) reach
undesirable levels, adjustments may be made to the dead space volume (e.g., within
rebreathing element 30), or volume of rebreathed gases, to the concentration of oxygen
or carbon dioxide in the other inhaled gases, or to any combination of the foregoing.
Such adjustment may be made automatically, such as by processing element 220,
which, of course, operates under control of appropriate programming and
communicates with one or more of a ventilator, valves (e.g.t bypass valve 78 (FIG. 7))
of the anesthesia reversal system 10. Alternatively, adjustment of the dead space may
be effected semiautomaticaHy, such as in accordance with instructions provided by a
processing element, or manually.
By combining a filter 20 and an element for increasing the amount of carbon
dioxide inhaled by individual I (e.g., with a rebreathing element 30 or carbon dioxide
infusion element 130) in an anesthesia reversal apparatus of the present invention,

WO 2004/098688 PCT/US2004/012291
-15-
ventilation of an individual I may be increased while maintaining normal to high PaCO2
levels, which maintains or increases blood flow levels and, thus, the rate at which
anesthetic agents may be removed from the brain as the increased ventilation improves
the rate at which anesthetic agents are removed from the blood and, thus, exhaled by
individual I.
While much of the description provided herein focuses on the reversal of
general anesthesia, it should be appreciated that the apparatus and methods of the
present invention are useful for reversing the effects of any type of inhaled anesthesia,
whether or not such inhaled anesthetic agents have a general anesthetic effect.
Although the foregoing description contains many specifics, these should not be
construed as limiting the scope of the present invention, but merely as providing
illustrations of some of the presently preferred embodiments. Similarly, other
embodiments of the invention may be devised which do not depart from the spirit or
scope of the present invention. Features from different embodiments may be employed
in combination. The scope of the invention is, therefore, indicated and limited only by
the appended claims and their legal equivalents, rather than by the foregoing
description. All additions, deletions and modifications to the invention as disclosed
herein which fall within the meaning and scope of the claims are to be embraced
thereby.

WO 2004/098688 PCT/US2004/012291
-16-
CLAIMS
What is claimed is:
1. An apparatus for facilitating emergence of a subject from inhaled
anesthesia, comprising:
means for decreasing a concentration of anesthetic agents in blood leaving the lungs
and flowing into the brain of the subject;
means for increasing blood flow through the brain of the subject; and
means for preventing the subject from inhaling previously exhaled anesthetic agents.
2. The apparatus of claim 1, wherein the means for increasing blood flow
comprises means for controlling an amount of carbon dioxide inhaled by the subject.
3. An apparatus for facilitating emergence of a subj ect from inhaled
anesthesia, comprising:
means for increasing ventilation of the subject;
means for causing the subject to inhale gases including at least an atmospheric amount
of carbon dioxide; and
means for preventing the subject from inhaling previously exhaled anesthetic agents.
4. The apparatus of claim 3S wherein the means for causing comprises
means for controlling an amount of carbon dioxide inhaled by the subject
5. The apparatus of claim 2 or claim 4, wherein the means for controlling
comprises means for causing the subject to inhale air or a gas mixture with a fixed
concentration of carbon dioxide. '
6. The apparatus of claim 2 or claim 4, wherein the means for controlling
comprises means for causing the subject to inhale air or a gas mixture with an above
normal amount of carbon dioxide.

WO 2004/098688 PCT/US2004/012291
-17-
7. The apparatus of claim 6, wherein the means for controlling comprises
means for causing the subject to rebreathe previously exhaled gases.
8. The apparatus of claim 7, wherein the means for causing comprises
means for adjusting a volume of the previously exhaled gases.
9. The apparatus of claim 8, wherein the means for adjusting comprises
means for permitting a portion of the previously exhaled gases to escape a volume with
which the means for causing communicates.

10. The apparatus of claim 7, wherein the means for causing comprises
means for adjusting an amount of carbon dioxide in the previously exhaled gases.
11. The apparatus of claim 10, wherein the means for adjusting comprises
means for removing carbon dioxide from a portion of the previously exhaled gases.
12. The apparatus of any of claims 8 through 11, wherein the means for
adjusting comprises means for controlling a flow rate of fresh gases into a volume with
which the means for causing communicates.
13., The apparatus of any of claims 6 through 12, wherein the means for
causing comprises means for causing the subject to inhale air or a gas mixture which is
substantially free of anesthetic agents.
14. The apparatus of any of claims 6 through 13, wherein the means for
preventing comprises means for removing at least some anesthetic agents from the
previously exhaled gases.
15. The apparatus of claim 14, wherein the means for removing comprises
1 means for removing substantially all anesthetic agents from the previously exhaled
gases.

WO 2004/098688 PCT/US2004/012291
-18-
16. The apparatus of claim 14 or claim 15, wherein the means for removing
comprises means for filtering the previously exhaled gases.
17. The apparatus of any of claims 1 through 16, further comprising:
means for preventing the subject from inhaling pathogens.
18. A system for facilitating emergence of a subject from inhaled anesthesia,
comprising:
a filter for at least partially removing anesthesia from gases exhaled by the subject; and
a CO2 level-elevating component for causing the subject to inhale gases including an
above-normal amount of CO2.
19. The system of claim 18, wherein the CO2 level-elevating component
comprises a rebreathing component for causing the subject to inhale at least previously
exhaled gases.
20.. The system of claim 19, wherein the rebreathing component is
configured to cause the subject to inhale at least some previously exhaled gases that
have passed through the filter.
21. The system of claim 19 or claim 20, wherein the rebreathing component
is configured to facilitate partial rebreathing by the subject.
22. The system of claim 19 or claim 20, wherein the rebreathing component
is configured to facilitate total rebreathing by the subject.
i
23. The system of any of claims 19 through 22, wherein the rebreathing
component comprises a lengjtb. of conduit positioned between a Y-piece of a breathing
circuit and the filter.
24. The system of claim 23, wherein at least a portion of the length of
conduit is volume-adjustable.

WO 2004/098688 PCT/US2004/012291
-19-
25. The system of any of claims 19 through 22, wherein the rebreathing
component comprises a length of conduit including two ends, each of the two ends
communicating with the filter.
26. The system of claim 25, wherein at least a portion of the length of
conduit is volume-adjustable.
27. The system of any of claims 19 through 26, wherein the rebreathing
component comprises a dead space volume within a body of the filter and located on a
distal side of a filter element of the filter from the subject.

28. The system of claim 27, wherein the dead space volume is defined at
least partially by the body.
29. The system of claim 27 or claim 28, wherein the dead space volume is
configured to be adjusted.
30. The system of any of claims 25 through 29, wherein the rebreathing
component comprises:
a shunt line positioned between an inspiratory limb and an expiratory limb of a
breathing circuit along which the filter is positioned; and
a valve positioned along the shunt line for controlling a flow of gases therethrough.
31. The system of any of claims 25 through 29, wherein the rebreathing
component comprises at least a section of a circle system along which the filter is
positioned. ,
32. The system of claim 31, further comprising:
a valve for selectively directing at least some exhaled gases into or out of at least one of
the rebreathing component and the filter.
33. The system of any of claims 18 through 32, further comprising:
one of a circle system and a Bain system with which at least the filter communicates.

WO 2004/098688 PCT/US2004/012291
-20-
34. The system of claim 33, further comprising:
a valve for selectively directing at least some exhaled gases from the circle system or
the Bain system to the filter or for establishing communication between the CO2
level-elevating component and the circle system or the Bain system.
35. The system of any of claims 18 through 34, wherein the rebreatlung
component comprises an anesthesia breathing circuit with at least one of:
a removable carbon dioxide adsorber; and
a bypass conduit and valve associated therewith for causing-exhaled gases to bypass a
carbon dioxide adsorber of the anesthesia breathing circuit.
36. The system of claim 35, wherein the valve is configured to introduce at
least some gases exhaled by the subject into the filter or to establish communication
between the CO2 level-elevating component and the anesthesia breathing circuit,
37. The system of any of claims 18 through 36, wherein the CO2
level-elevating component comprises a CO2 infusion element.
38. The system of any of claims 18 through 37, wherein the filter is
configured to substantially remove anesthesia from the gases exhaled by the subject

39. The system of claim 38, wherein the filter is configured to reduce levels
of anesthesia that escape into the environment
40. The system of any of claims 18 through,39, wherein the filter includes
an adsorbent for at least a portion of the inhaled anesthesia.
41. The system of any of claims 18 through 40, wherein the filter comprises
' at least one of activated charcoal, crystalline silica, a lipid absorber, and a condensation
generating element

WO 2004/098688 PCT/US2004/012291
-21-
42. The system of any of claims 18 through 41, wherein the filter does not
substantially reduce an amount of at least one of carbon dioxide and oxygen in the
gases exhaled by the subject.
43. The system of any of claims 18 through 42, wherein the filter is further
configured to remove pathogens from gases inhaled by the subject.

An apparatus for reversing inhaled anesthesia, which is configured to be positioned along a breathing circuit or anesthesia de delivery circuit, includes a filter for removing one or more anesthesia agents from gasses passing threat rough as well as a component for elevating CO2 level in gasses that are to be inhaled by an individual, The apparatus is configured to be positioned between Y connector of the breathing circuit and portion of the breathing circuit that interface with the individual, The CO2 level elevating components facilitates an increase in the ventilation of the individual without resulting in a significant decrease in the individual’s P2CO2 level and thus, a decrease in the rate at which blood flows through the individual’s brain. The apparatus may cause an increase in a rate of the anesthetized individual’s ventilation while causing individual’ to inhale gasses with elevated amount of CO2 and while filtering anesthetic agent from such gasses.

Documents:

02455-kolnp-2005-abstract.pdf

02455-kolnp-2005-claims.pdf

02455-kolnp-2005-description complete.pdf

02455-kolnp-2005-drawings.pdf

02455-kolnp-2005-form 1.pdf

02455-kolnp-2005-form 3.pdf

02455-kolnp-2005-form 5.pdf

02455-kolnp-2005-international publication.pdf

2455-KOLNP-2005-CORRESPONDENCE.pdf

2455-KOLNP-2005-FORM 27.pdf

2455-KOLNP-2005-FORM-27.pdf

2455-kolnp-2005-granted-abstract.pdf

2455-kolnp-2005-granted-assignment.pdf

2455-kolnp-2005-granted-claims.pdf

2455-kolnp-2005-granted-correspondence.pdf

2455-kolnp-2005-granted-description (complete).pdf

2455-kolnp-2005-granted-drawings.pdf

2455-kolnp-2005-granted-examination report.pdf

2455-kolnp-2005-granted-form 1.pdf

2455-kolnp-2005-granted-form 13.pdf

2455-kolnp-2005-granted-form 18.pdf

2455-kolnp-2005-granted-form 3.pdf

2455-kolnp-2005-granted-form 5.pdf

2455-kolnp-2005-granted-gpa.pdf

2455-kolnp-2005-granted-others.pdf

2455-kolnp-2005-granted-reply to examination report.pdf

2455-kolnp-2005-granted-specification.pdf

abstract-02455-kolnp-2005.jpg


Patent Number 235096
Indian Patent Application Number 2455/KOLNP/2005
PG Journal Number 26/2009
Publication Date 26-Jun-2009
Grant Date 24-Jun-2009
Date of Filing 01-Dec-2005
Name of Patentee AXON MEDICAL, INC.
Applicant Address 2463 SOUTH 3850 WEST, #200, SALTLAKE CITY, UT 84120-2356,
Inventors:
# Inventor's Name Inventor's Address
1 ORR, JOSEPH, A 2645 SACKETT DRIVE, PARK CITY, UT 84098
2 SAKATA, DEREK, JO 4576 WALLACE LANE, SALTLAKE CITY UT 84117
3 WESTENSKOW, DWAYNE, R FIDEL H. SILVA, PH. D., 3439 EAST WINESAP ROAD, SALT LAKE CITY UT 84121
PCT International Classification Number A61M 16/00
PCT International Application Number PCT/US2004/012291
PCT International Filing date 2004-04-20
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 60/466,934 2003-05-01 U.S.A.
2 10/680,469 2003-10-07 U.S.A.